Esperion Investor Day: Lighting the Way for Phase 2b Results

September 5, 2014
Tim Mayleben
President and Chief Executive Officer

On July 29th, Esperion held its inaugural investor day in New York City, with a tightly-packed agenda for the half-day event that included presentations from several of the world’s leading experts in their respective fields.  It was an exciting and informative day! Dr. James McKenney, President and CEO of National Clinical Research, and Professor Emeritus… Read More

Reflections One Year Post-IPO

June 26, 2014
Tim Mayleben
President and Chief Executive Officer

One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More

Posted In: Company News

“The IPO Age: Onward and Upward” — Insights from the BioCentury TV Roundtable

May 7, 2014
Tim Mayleben
President and Chief Executive Officer

Recently, I had the pleasure of participating in a roundtable, “The IPO Age: Onward and Upward,” to review how the recent spate of biotech IPOs belies the earlier struggle to finance trials and product development. I was joined by fellow biotech CEOs, Jeff Abbey of Argos and Scott Koenig of MacroGenics, for an engaging and… Read More

Looking Back on a Successful 2013 and a Glance Ahead at a Promising 2014

December 31, 2013
Tim Mayleben
President and Chief Executive Officer

Esperion had an incredible year in 2013 with more successes, both clinically and financially, than in any other year since we were founded in April 2008 as the new Esperion. We executed on all of our milestones – all toward our goal of bringing ETC-1002 to market. A unique, first-in-class, oral, once-daily investigational small molecule,… Read More

Posted In: Company News